<DOC>
	<DOCNO>NCT02325986</DOCNO>
	<brief_summary>The purpose study evaluate efficacy toxicity radiotherapy concurrently weekly chemotherapy 5-FU cisplatin patient postoperative locoregional recurrence esophageal squamous cell carcinoma .</brief_summary>
	<brief_title>Concurrent Radiotherapy Weekly Chemotherapy PF Postoperative Locoregional Recurrence Esophageal Cancer</brief_title>
	<detailed_description>The optimal management postoperative locoregional recurrence oesophageal squamous cell carcinoma still controversial . Several study report feasibility efficacy concurrent chemoradiotherapy ( CCRT ) , mostly three-weekly four-weekly schedule chemotherapy . However , treatment compliance quite satisfactory , probably due treatment-related toxicity . Since CCRT weekly chemotherapy regimen demonstrate favorable toxicity profile well promise survival certain type cancer , investigator aim evaluate efficacy toxicity radiotherapy concurrently weekly chemotherapy 5-fluorouracil ( 5-FU ) cisplatin patient postoperative locoregional recurrence oesophageal squamous cell carcinoma investigator center.The prescribe dose radiotherapy generally 60Gy/28fr tumor 50Gy/28fr clinical target volume.The concomitant chemotherapy cisplatin 25mg/m2 day 1 , 5-FU 1176mg/m2 day 1-3 , repeat weekly 4 week .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . R0 resection primary esophageal squamous cell carcinoma twoincision esophagectomy ( Ivor Lewis approach ) 25 threeincision ( right thoracotomy , midline laparotomy leave cervical incision ) esophagectomy cervical esophagogastric anastomosis . 2 . Absence previous thoracic radiotherapy . 3 . Cervical and/or thoracic postoperative recurrence ( biopsy proven positron emission tomography/computed tomography ( PET/CT ) proven followup compute tomography ( CT ) show progression disease ) . 4 . Absence distant metastasis recurrence . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) â‰¤ 2 1 . Younger 18 old 70 year age . 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status 3 3 . Other cancer history . 4 . Serious cardiac , liver , pulmonary disease . 5 . Previous radiotherapy history</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>radiotherapy</keyword>
	<keyword>esophageal carcinoma</keyword>
	<keyword>chemotherapy</keyword>
</DOC>